Prostate Adenocarcinoma Clinical Trials

55 recruiting

Prostate Adenocarcinoma Trials at a Glance

76 actively recruiting trials for prostate adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 34 trials, with the heaviest enrollment activity in Los Angeles, Chicago, and Seattle. Lead sponsors running prostate adenocarcinoma studies include Jonsson Comprehensive Cancer Center, Mayo Clinic, and NRG Oncology.

Browse prostate adenocarcinoma trials by phase

Treatments under study

About Prostate Adenocarcinoma Clinical Trials

Looking for clinical trials for Prostate Adenocarcinoma? There are currently 55 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 76 trials

Recruiting
Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting
Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Not Applicable

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Prostate CancerProstate NeoplasmProstate Adenocarcinoma
University of Chicago180 enrolled1 locationNCT05710380
Recruiting

High-Risk prostatE Cancer radiatiOn Versus surgERy

Prostate CancerProstate Adenocarcinoma
Comprehensive Cancer Centre The Netherlands837 enrolled28 locationsNCT05931419
Recruiting
Phase 1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Adenocarcinoma
City of Hope Medical Center30 enrolled1 locationNCT07219147
Recruiting
Phase 1Phase 2

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
Vadim S Koshkin30 enrolled1 locationNCT05113537
Recruiting
Phase 1

PSMA PET Response Guided SabR in High Risk Pca

Prostate Adenocarcinoma
University of Texas Southwestern Medical Center20 enrolled2 locationsNCT06044857
Recruiting
Phase 2

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Prostate Adenocarcinoma
National Cancer Institute (NCI)90 enrolled5 locationsNCT06022822
Recruiting
Phase 1Phase 2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Michigan Rogel Cancer Center39 enrolled3 locationsNCT06616155
Recruiting
Phase 3

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

Prostate CancerProstate Adenocarcinoma
Curium US LLC439 enrolled43 locationsNCT06235151
Recruiting
Phase 3

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaCastration-Sensitive Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,260 enrolled177 locationsNCT06931340
Recruiting
Phase 3

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVA Prostate Cancer AJCC v8
NRG Oncology1,209 enrolled398 locationsNCT05946213
Recruiting
Phase 2

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Prostate Adenocarcinoma
Stephen Freedland138 enrolled3 locationsNCT05832086
Recruiting
Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+1 more
ECOG-ACRIN Cancer Research Group804 enrolled303 locationsNCT04423211
Recruiting
Not Applicable

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

ObesityProstate AdenocarcinomaCancer Survivor+17 more
Roswell Park Cancer Institute50 enrolled1 locationNCT03880422
Recruiting
Not Applicable

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

Stage III Prostate Cancer AJCC v8Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8+1 more
Mayo Clinic144 enrolled5 locationsNCT06325046
Recruiting
Phase 2

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Prostate Adenocarcinoma
Hackensack Meridian Health54 enrolled3 locationsNCT06798558
Recruiting
Not Applicable

Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

Prostate AdenocarcinomaOligorecurrenceIliac Nodal Disease+2 more
University Health Network, Toronto26 enrolled1 locationNCT06831032
Recruiting
Phase 2

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Prostate Adenocarcinoma+1 more
Mayo Clinic30 enrolled1 locationNCT07025369
Recruiting
Phase 2

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Prostate AdenocarcinomaCastration Sensitive Prostate Cancer
Ontario Clinical Oncology Group (OCOG)162 enrolled3 locationsNCT06654336